Tenosynovial giant cell tumour: the decisions you may face

Cancer page →Second-opinion finder →

3 treatment settings, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Early / localised

Localised TGCT

One path named

Marginal excision; recurrence is uncommon and re-excision is curative in most cases.

Guideline

NCCN Soft Tissue Sarcoma; TGCT consensus (Stacchiotti, Cancer Treat Rev 2023)

The path, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Questions to ask about this decision

Is Limb-salvage surgery and endoprosthetic reconstruction the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma; TGCT consensus (Stacchiotti, Cancer Treat Rev 2023)), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (localised tgct), which of the standard options do you recommend and why?
Why: Guideline options include: Marginal excision; recurrence is uncommon and re-excision is curative in most cases.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Diffuse TGCT, resectable

One path named

Open or arthroscopic synovectomy by a sarcoma orthopaedic team; consider neoadjuvant CSF1R inhibition for large tumours (trial setting).

The path, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Questions to ask about this decision

Is Limb-salvage surgery and endoprosthetic reconstruction the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (diffuse tgct, resectable), which of the standard options do you recommend and why?
Why: Guideline options include: Open or arthroscopic synovectomy by a sarcoma orthopaedic team; consider neoadjuvant CSF1R inhibition for large tumours (trial setting).

Add these to your appointment list, or take the full question set for this cancer.

Second line

Diffuse TGCT where surgery would cause severe morbidity or after recurrence

4 optionsCompare side by side →

CSF1R inhibitor: vimseltinib (MOTION) or pexidartinib (ENLIVEN, with REMS hepatic monitoring); imatinib or nilotinib off label where neither is available.

Guideline

NCCN · Category 2A

The options, in plain words

VimseltinibApprovedSmall-molecule kinase inhibitor (CSF1R)

Vimseltinib is a pill approved in February 2025 for tenosynovial giant cell tumour, a benign but destructive joint tumour, offering an alternative to repeated surgery.

PexidartinibApprovedSmall-molecule CSF1R/KIT/FLT3 inhibitor

Pexidartinib is the first drug for tenosynovial giant cell tumour, a benign but destructive joint tumour; it is effective but has liver toxicity that requires a restricted programme.

ImatinibApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)

The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.

NilotinibApprovedSmall-molecule BCR-ABL1 TKI (second generation)

Nilotinib is a second-generation CML pill that produces deeper responses faster than imatinib, at the cost of cardiovascular and metabolic side effects.

The evidence behind it

MOTION Phase 3 NCT05059262 2024123 peopleevidence 68
Tests Vimseltinib
Symptomatic tenosynovial giant cell tumour not amenable to surgery: vimseltinib vs placebo
ORR 40% vs 0%.
Objective response rate at week 25 (%): Vimseltinib 40 (n=83) vs Placebo 0 (n=40) · source

The main trade-offs on record

Imatinib all recorded rates →

Take with a meal and a large glass of water.

Nilotinib all recorded rates →

Take on an empty stomach (no food 2 hours before or 1 hour after): food raises exposure up to 82% and QT risk.
Known QT prolongation. Boxed warning for QT prolongation and sudden death: avoid QT-prolonging drugs; ECG at baseline, 7 days and after dose changes; correct potassium and magnesium.
Reduce dose in impairment per label.

Questions to ask about this decision

Between Vimseltinib, Pexidartinib, Imatinib and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in MOTION, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (diffuse tgct where surgery would cause severe morbidity or after recurrence), which of the standard options do you recommend and why?
Why: Guideline options include: CSF1R inhibitor: vimseltinib (MOTION) or pexidartinib (ENLIVEN, with REMS hepatic monitoring); imatinib or nilotinib off label where neither is available.
Am I a candidate for Vimseltinib, Pexidartinib, Imatinib or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of MOTION apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care

Tenosynovial giant cell tumour: the decisions you may face

Cancer page →Second-opinion finder →

Early / localised

Localised TGCT

One path named

Marginal excision; recurrence is uncommon and re-excision is curative in most cases.

Guideline

NCCN Soft Tissue Sarcoma; TGCT consensus (Stacchiotti, Cancer Treat Rev 2023)

The path, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Questions to ask about this decision

Is Limb-salvage surgery and endoprosthetic reconstruction the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma; TGCT consensus (Stacchiotti, Cancer Treat Rev 2023)), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (localised tgct), which of the standard options do you recommend and why?
Why: Guideline options include: Marginal excision; recurrence is uncommon and re-excision is curative in most cases.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Diffuse TGCT, resectable

One path named

Open or arthroscopic synovectomy by a sarcoma orthopaedic team; consider neoadjuvant CSF1R inhibition for large tumours (trial setting).

The path, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Questions to ask about this decision

Is Limb-salvage surgery and endoprosthetic reconstruction the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (diffuse tgct, resectable), which of the standard options do you recommend and why?
Why: Guideline options include: Open or arthroscopic synovectomy by a sarcoma orthopaedic team; consider neoadjuvant CSF1R inhibition for large tumours (trial setting).

Add these to your appointment list, or take the full question set for this cancer.

Second line

Diffuse TGCT where surgery would cause severe morbidity or after recurrence

4 optionsCompare side by side →

CSF1R inhibitor: vimseltinib (MOTION) or pexidartinib (ENLIVEN, with REMS hepatic monitoring); imatinib or nilotinib off label where neither is available.

Guideline

NCCN · Category 2A

The options, in plain words

VimseltinibApprovedSmall-molecule kinase inhibitor (CSF1R)

Vimseltinib is a pill approved in February 2025 for tenosynovial giant cell tumour, a benign but destructive joint tumour, offering an alternative to repeated surgery.

PexidartinibApprovedSmall-molecule CSF1R/KIT/FLT3 inhibitor

Pexidartinib is the first drug for tenosynovial giant cell tumour, a benign but destructive joint tumour; it is effective but has liver toxicity that requires a restricted programme.

ImatinibApprovedSmall-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)

The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.

NilotinibApprovedSmall-molecule BCR-ABL1 TKI (second generation)

Nilotinib is a second-generation CML pill that produces deeper responses faster than imatinib, at the cost of cardiovascular and metabolic side effects.

The evidence behind it

MOTION Phase 3 NCT05059262 2024123 peopleevidence 68
Tests Vimseltinib
Symptomatic tenosynovial giant cell tumour not amenable to surgery: vimseltinib vs placebo
ORR 40% vs 0%.
Objective response rate at week 25 (%): Vimseltinib 40 (n=83) vs Placebo 0 (n=40) · source

The main trade-offs on record

Imatinib all recorded rates →

Take with a meal and a large glass of water.

Nilotinib all recorded rates →

Take on an empty stomach (no food 2 hours before or 1 hour after): food raises exposure up to 82% and QT risk.
Known QT prolongation. Boxed warning for QT prolongation and sudden death: avoid QT-prolonging drugs; ECG at baseline, 7 days and after dose changes; correct potassium and magnesium.
Reduce dose in impairment per label.

Questions to ask about this decision

Between Vimseltinib, Pexidartinib, Imatinib and the other options, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in MOTION, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (diffuse tgct where surgery would cause severe morbidity or after recurrence), which of the standard options do you recommend and why?
Why: Guideline options include: CSF1R inhibitor: vimseltinib (MOTION) or pexidartinib (ENLIVEN, with REMS hepatic monitoring); imatinib or nilotinib off label where neither is available.
Am I a candidate for Vimseltinib, Pexidartinib, Imatinib or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of MOTION apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.